Chemoembolization with HepaSpheres in the treatment of recurrent pelvic tumors

Transarterial chemoembolization of the main vessels feeding the tumor is a minimally invasive procedure, which is intended to block off the blood supply to the tumor and to deliver a cytotoxic agent to tumor cells. Initially, this method was used in emergency cases, but later it gained the trust of clinicians, who began to use it in non-emergency patients with clinical manifestations, when angiography showed well-supplied tumors inaccessible for ablation or surgical removal, including those in non-standard difficult cases. Selective catheterization of dominant arteries in recurrent tumors along with chemoembolization with drug-eluting microspheres is extremely challenging, since most of recurrent tumors have a well-developed neovascular network. HepaSphere microspheres, due to their hydrophilicity and high biological compatibility with tissues, allow the deposition of a chemotherapeutic agent in the tumor. This therapy provides pronounced hemostatic and antitumor effects confirmed by morphological and immunohistochemical examination. Currently, transarterial chemoembolization is mainly used for primary tumors and becomes increasingly popular as an element of combination therapy for patients with pelvic tumors. In this article, we analyze clinical data for 14 patients with recurrent pelvic tumors who underwent chemoembolization with HepaSpheres loaded with doxorubicin or irinotecan as a part of their palliative care.

1. De Foucher T., Bendifallah S., Ouldamer L. et al. Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group. Eur J Surg Oncol 2019;45(4):659–65. DOI: 10.1016/j.ejso.2018.11.014.

2. Lee N., Kim S.I., Lee M. et.al. Bevacizumab efficacy and recurrence pattern of persistent and metastatic cervical cancer. In Vivo 2019;33(3):863–8. DOI: 10.21873/invivo.11551.

3. Pfaendler K.S., Tewari K.S. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 2016; 214(1):22–30. DOI: 10.1016/j.ajog.2015.07.022.

4. Bandyopadhyay A., Mukherjee U., Ghosh S. et al. Pattern of failure with locally advanced cervical cancer – a retrospective audit and analysis of contributory factors. Asian Pac J Cancer Prev 2018;19(1):73–9. DOI: 10.22034/APJCP.2018.19.1.73.

5. Moore D.H., Blessing J.A., McQuellon R.P. et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22(15):3113–9. DOI: 10.1200/JCO.2004.04.170.

6. Monk B.J., Sill M.W., McMeekin D.S. et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2009;27(28):4649–55. DOI: 10.1200/JCO.2009.21.8909.

7. Heaston D.K., Mineau D.E., Brown B.J. et al. Transcatheter arterial embolization for control of persistent massive puerperal hemorrhage after bilateral surgical hypogastric artery ligation. AJR Am J Roentgenol 1979;33:152–4.

8. Wang H.X., Li S.H., Zhao H.Y. Effect of different preoperative neoadjuvant chemotherapy on cervical cancer angiogenesis and cell proliferation. Journal of Hainan Medical University 2016;22(20):115–8.

9. Instruction for loading cytostatic agents into the HepaSphere microspheres. (In Russ.).

10. Tinelli A., Prudenzano R., Malvasi A. et al. Emergency endovascular nanopharmacologic treatment in advanced gynecological cancers. Int J Gynecol Cancer 2010;20:1250–5.

11. Kedrova A.G., Lebedev D.P., Shablovskiy O.R. et al. Chemoembolization of pelvic vessels as a stage of treatment for cervical and uterine cancer. Klinicheskaya praktika = Clinical practice 2016;2:50–6. (In Russ.).

12. Yin Y.J., Li H.Q., Sheng X.G. et al. The treatment of pelvic locoregional recurrence of cervical cancer after radical surgery with intensity-modulated radiation therapy compared with conventional radiotherapy: a retrospective study. Int J Gynecol Cancer 2015;25(6):1058–65.

13. Usuki N., Hirokawa K., Tashiro T. et al. Intraarterial chemotherapy for uterine cervical adenocarcinoma: evaluation of its efficacy as neoadjuvant therapy. Nihon Igaku Hoshasen Gakkai Zasshi 1999;59(12):670–3.

14. Tsubamoto H., Wada R., Kanazawa R. et al. Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma. J Clin Oncol 2009;27(suppl):e16518. DOI: 10.1200/jco.2009.27.15_suppl.e16518.